PDCD1 and melanoma: These include combining the anti-CTLA antibody, ipilimumab with the anti-KIR antibody, IPH2102 (lirilumab) to treat advanced tumors (NCT01750580) and an anti-PD-1 antibody (nivolumab) in combination with either ipilimumab to treat melanoma (NCT01024231) or with lirilumab to treat solid tumors (NCT01714739).